Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
TYRA
$33.88
$
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Beta
1.076
Average Volume
Market Cap
Last Dividend
CIK
0001863127
ISIN
US90240B1061
CUSIP
90240B106
CEO
Todd Harris
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
60
IPO Date
2021-09-15
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium | CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU). | PRNewsWire | 2026-02-23 17:30:00 |
| Tyra Biosciences to Participate in Upcoming Investor Conferences | CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: 36th Annual Oppenheimer Life Sciences Healthcare Conference Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Thursday, February 26, 2026 at 12:00pm ETLocation: Virtual 46th Annual TD Cowen Healthcare Conference Format: Hybrid presentation & fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, March 4th, 2026 at 11:50am ETLocation: Boston, MA Leerink Global Healthcare Conference Format: One-on-one investor meetingsDate: March 8-11, 2026Location: Miami, FL 2026 Jefferies Biotech on the Beach Summit Format: One-on-one investor meetingsDate: March 9-11, 2026Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Format: One-on-one investor meetingsDate: March 10-12, 2026Location: Miami, FL A live webcast of the presentations can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event. | PRNewsWire | 2026-02-19 16:05:00 |
| AquaBounty Technologies (NASDAQ:AQB) versus Tyra Biosciences (NASDAQ:TYRA) Head to Head Analysis | AquaBounty Technologies (NASDAQ: AQB - Get Free Report) and Tyra Biosciences (NASDAQ: TYRA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Institutional and Insider Ownership 8.9% of AquaBounty | Defense World | 2025-12-28 02:35:10 |
| Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally | Robert More reported the sale of 246,871 shares on Nov. 21 as part of a Rule 10b5-1 trading plan. The director still owns nearly 4 million shares, worth approximately $77.6 million. | The Motley Fool | 2025-12-23 13:27:00 |
| Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of “Moderate Buy” from Brokerages | Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has given a strong buy | Defense World | 2025-12-23 01:12:59 |
| Tyra Biosciences (NASDAQ:TYRA) Hits New 1-Year High – Here’s Why | Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) hit a new 52-week high during trading on Friday. The stock traded as high as $24.26 and last traded at $23.9230, with a volume of 86224 shares trading hands. The stock had previously closed at $22.99. Wall Street Analyst Weigh In A number of brokerages recently | Defense World | 2025-12-21 03:32:55 |
| Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer | CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of two key members of its leadership team: Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer. | PRNewsWire | 2025-12-01 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G | 2026-02-20 | 2026-02-20 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 4 | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 4 | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2025-12-19 | 2025-12-19 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-01 | 2025-12-01 | View Filing |
| 3 | 2025-12-01 | 2025-12-01 | View Filing |
| 8-K | 2025-12-01 | 2025-12-01 | View Filing |
| 4 | 2025-11-25 | 2025-11-25 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-11-05 | 2025-11-05 | View Filing |
| 4 | 2025-09-17 | 2025-09-17 | View Filing |
| 8-K | 2025-08-22 | 2025-08-21 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 4 | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-11 | 2025-06-11 | View Filing |
| SC 13D/A | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 8-K | 2025-05-29 | 2025-05-29 | View Filing |
| EFFECT | 2025-05-19 | 2025-05-19 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G/A | 2025-05-12 | 2025-05-12 | View Filing |
| S-3 | 2025-05-08 | 2025-05-08 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| ARS | 2025-04-18 | 2025-04-18 | View Filing |
| DEFA14A | 2025-04-18 | 2025-04-18 | View Filing |
| DEF 14A | 2025-04-18 | 2025-04-18 | View Filing |
| SC 13D/A | 2025-03-31 | 2025-03-31 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 4 | 2025-03-18 | 2025-03-18 | View Filing |
| 4 | 2025-03-18 | 2025-03-18 | View Filing |
| SC 13G | 2025-03-06 | 2025-03-06 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-01-31 | 2025-01-31 | View Filing |
| 3 | 2025-01-31 | 2025-01-31 | View Filing |
| 8-K | 2025-01-29 | 2025-01-29 | View Filing |
| 4 | 2025-01-27 | 2025-01-27 | View Filing |
| 4 | 2025-01-21 | 2025-01-21 | View Filing |
| SC 13G/A | 2025-01-21 | 2025-01-21 | View Filing |
| SC 13D/A | 2024-12-06 | 2024-12-06 | View Filing |
| 4 | 2024-11-26 | 2024-11-26 | View Filing |
| SC 13D/A | 2024-11-19 | 2024-11-19 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13D/A | 2024-11-13 | 2024-11-13 | View Filing |
| 4 | 2024-11-13 | 2024-11-13 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| 4 | 2024-11-08 | 2024-11-08 | View Filing |
| 10-Q | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| 4 | 2024-11-06 | 2024-11-06 | View Filing |
| 4 | 2024-11-01 | 2024-11-01 | View Filing |
| 4 | 2024-11-01 | 2024-11-01 | View Filing |
| 8-K | 2024-10-28 | 2024-10-28 | View Filing |
| 8-K | 2024-10-25 | 2024-10-25 | View Filing |
| SC 13D/A | 2024-10-22 | 2024-10-22 | View Filing |
| 4 | 2024-10-22 | 2024-10-22 | View Filing |
| 3 | 2024-10-22 | 2024-10-22 | View Filing |
| 4 | 2024-10-22 | 2024-10-22 | View Filing |
| SC 13D/A | 2024-10-22 | 2024-10-22 | View Filing |
| 4 | 2024-10-22 | 2024-10-22 | View Filing |
| 8-K | 2024-10-18 | 2024-10-18 | View Filing |
| 4 | 2024-10-17 | 2024-10-17 | View Filing |
| SC 13D/A | 2024-10-15 | 2024-10-15 | View Filing |
| SC 13D/A | 2024-10-15 | 2024-10-15 | View Filing |
| 4 | 2024-10-02 | 2024-10-02 | View Filing |
| 4 | 2024-09-25 | 2024-09-25 | View Filing |
| 4 | 2024-09-20 | 2024-09-20 | View Filing |
| 4 | 2024-09-17 | 2024-09-17 | View Filing |
| 4 | 2024-09-17 | 2024-09-17 | View Filing |
| 4 | 2024-09-10 | 2024-09-10 | View Filing |
| 3 | 2024-09-10 | 2024-09-10 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Pivot Points Strategy | 37.43% | 0.95 | 20 | 1.31 | 10.2 | 28.87 |
| Volume Gap | 25.94% | 0.99 | 39 | 0.52 | 0.47 | 10.26 |
| Swarm Intelligence Strategy | 20.52% | 0.98 | 39 | 0.48 | 0.31 | 4.84 |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxx | xxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxx | x | xx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |